Frazier Financial Advisors LLC Raises Stock Position in Novo Nordisk A/S (NYSE:NVO)

Frazier Financial Advisors LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 27.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,370 shares of the company’s stock after buying an additional 514 shares during the period. Frazier Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $282,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Zions Bancorporation N.A. lifted its holdings in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after acquiring an additional 37,346 shares during the last quarter. Natixis Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the last quarter. Private Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 155.1% in the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after acquiring an additional 20,188 shares during the last quarter. Finally, Buckingham Capital Management Inc. bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $3,874,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 3.4 %

Shares of NVO opened at $101.74 on Friday. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The company has a 50-day moving average of $118.58 and a 200 day moving average of $129.59. The firm has a market capitalization of $456.56 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.